COVID-19 TESTING PLATFORM FOR ENTERPRISES

In cooperation with QLife
ABOUT QLIFE

_ QLife Aps founded in 2018
_ QLife Holding founded in 2019
  _ 5 MDKK from Danish Preseed Ventures, KMD Ventures and two Swedish business angels.
  _ Pre IPO in August 2019 raised 19 MSEK

_ Founders have 20 years of experience in IVD (In-Vitro Diagnostics)
  _ IVD = diagnostics of samples taken from the human body i.e. blood
“Qlife is a high-tech medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it the most.”

“The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient’s doctor, clinic or hospital via smartphone and computer.”
2018 Q2 Qlife is founded in Denmark
2018 Q4 *KMD Venture invests in Qlife
2019 Q3 Cooperation between Qlife and *KMD DIMA, on personalized medicine for cancer treatment, *Herlev Hospital
2020 Q1 First CE approval for Qlife
2020 Q1 Qlife is listed on the Nasdaq First North Growth Market in Stockholm
2020 Q2 Cooperation between Qlife and KMD DIMA on Covid-19 testing

* KMD Venture, a part of KMD A/S focusing on start-up investments
KMD DIMA, KMD department for Data, Information Management and Analytics
Herlev Hospital, a part of Copenhagen region, one of the largest hospital within the region
## INTRODUCTION TO QLIFE

A unique biomarker test platform

### THE COMPANY

- Qlife Aps is located in Copenhagen, Denmark
- Qlife is a medtech company, which designs and manufactures the self-testing biomarker device platform called **Egoo.Health** with the capacity to perform analyses that correlate above 99% with high performance lab instruments
- Egoo works as a platform in the sense that it can potentially test everything measurable from blood. As a result, expanding the number of biomarker tests only requires the development of new capsules
- Egoo organisation is well established and ready for scaling

### THE PRODUCT

- Egoo. Health, a decentralized or personal biomarker device, is a **self-testing platform** for accurate, low cost and easy-to-use diagnostics
- Egoo. Health delivers identical performance as central laboratories, but differentiates itself by being accessible, portable and exoteric
- The test results are received within 10 minutes, and the simplicity of the system makes it operable by everyone
- Egoo is developed to leverage **Cloud technology**. All tests are therefore available from everywhere

### QLIFE FOUNDERS

- **Thomas Warthoe** | CEO and co-founder
- **Peter Warthoe** | CSO and co-founder
- **Lars Bangsgaard** | CFO and co-founder

- The founders have spent the last 20 years in the IVD (In-Vitro Diagnostic) industry building small high-tech medical devices to partner with leading IVD companies and have gained solid know-how and experience in product development, regulatory approvals and business operations.
- The management team consist of experienced professionals who have more than 70 years of combined experience from the medtech industry
THREE BRANCHES

LITTLE EGOO

BIG EGOO

COVID-19 SERVICE

Testing for

Bio-markers Covid-19

Covid-19

Covid-19
LITTLE EGO – WHERE IT ALL BEGAN

UNIQUE & SMART DESIGN

A combination of biochemistry and bioengineering technology.

Raw data is transferred to the cloud for immediate analysis.

The app synchronises all data and delivers the results.

The system IoT infrastructure facilitates easy software updates.

LITTLE EGO

BIG EGO

SERVICE
THE FOUR KEY COMPONENTS OF THE SOLUTION
A UNIQUE TECHNOLOGY ENABLES DECENTRALIZED BIOMARKER TESTING

1. THE DEVICE
   - The Egoo device is affordable and accessible for everyone
   - Support protein and DNA/RNA test → can measure almost any biomarker of protein or DNA nature.
   - Results delivered within 10 – 20 minutes
   - Accuracy as in laboratories

2. THE CAPSULE
   - Scalable: Capsule for several different biomarkers
     - Each capsule can measure a maximum of 1-2 biomarkers.
     - Each biomarker is in a separate capsule

3. THE APP
   - Speed: Fast access to test results
     - One app – multiple devices

4. THE DIMA Health CLOUD
   - Cloud driven: Secure and solid infrastructure
     - Secure and safe sharing of results with approved healthcare authorities and professionals
EGOO SOLUTION VERSUS EXISTING METHODS
THE EGOO SOLUTION IS FASTER, SMOOTHER AND ENABLES DECENTRALIZED TESTING

EXISTING METHOD

A blood sample or swap is taken at a hospital or a doctor’s clinic

The doctor sends the sample to a central laboratory

The actual test is done at the laboratory

The doctor forwards the results to the patient

The results of the test are sent to the doctor

Timeframe: Up to three days

THE EGOO SOLUTION

The test is taken, and the results are delivered in at decentralized setting

The healthcare professionals can see the results from the test in their systems

Timeframe: 10-20 min.

THE NEW PARADIGM

DECENTRALIZED DIAGNOSTICS

LITTLE EGOO  BIG EGOO  SERVICE
Mass testing

Centralized at laboratory

Delivery of chemistry (SIBA) for analyzing e.g. Covid-19 on existing PCR machines (e.g. in hospitals)

Faster than normal PCR method

Up to 96 samples per round. If samples are pooled, up to 480 samples.
TWO WAYS OF TESTING

Individual test
Decentralized (at home)

Mass testing
Centralized (at laboratory)
COVID-19 SERVICE

1. PREPARE FOR TEST
2. TAKE SWAB
3. DELIVER SWABS
4. SWABS ANALYZED
5. RESULT IN PORTAL

Answer 4-24 hours after arrival at lab
COVID-19 SERVICE CUSTOMERS

DIVISIONSFORENINGEN

DBU

CBS

AARSLEFF

TREK

BADMINTON DANMARK


dr

PROFILE PICTURES

Segafredo

Odense Teater

deceuninck

Odense Teater

DIVISIONSFORENINGEN

Emirates

©KMD
Internal - KMD A/S

LITTLE EGOO

BIG EGOO

SERVICE

13